213 filings
Page 2 of 11
8-K
hcdae01ikm5xvqed4b
13 Jan 22
Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Revenue Guidance for 2022
7:30am
8-K
urohmedl1x3j u1
3 Dec 21
Changes in Registrant's Certifying Accountant
4:38pm
8-K
1028olkrcd
8 Oct 21
Nephros Announces Preliminary Results for Third Quarter of 2021
7:45am
8-K
5b5hv
2 Sep 21
Nephros Appoints Wes Lobo to Chief Commercial Officer
8:53am
8-K
4ijdqs9
5 Aug 21
Results of Operations and Financial Condition
4:27pm
8-K
xprpv
12 Jul 21
Strategic Acquisition Accelerates Pathogen Detection Product Development
10:30am
8-K
qb38msik
8 Jul 21
Nephros Announces Preliminary Results for Second Quarter of 2021
9:22am
8-K
vhcbob bf5
20 May 21
Departure of Directors or Certain Officers
5:20pm
8-K
7mardb
6 May 21
Net Revenue of $2.7 Million; Highest First Quarter in Company History
4:15pm
8-K
nnctnl0 58dip
5 Apr 21
Nephros Announces Preliminary Results for First Quarter of 2021
7:47am
8-K
7vxwhdhldh4
31 Mar 21
Departure of Directors or Certain Officers
4:15pm
8-K
rrcbwd wsyc8nxg6
29 Mar 21
Other Events
5:15pm
8-K
blb2j4sctp
1 Mar 21
Nephros Reports 2020 Fourth Quarter and Full Year Financial Results
4:20pm
8-K
c2red3eko
3 Feb 21
Departure of Directors or Certain Officers
5:10pm
8-K
d5nwc1y6
12 Jan 21
Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
10:51am
8-K
8xkyuhg9
5 Nov 20
Nephros Appoints Dan D’Agostino as CFO
4:18pm
8-K
b5fgrqsj9n
29 Oct 20
Departure of Directors or Certain Officers
4:15pm
8-K
cvl4qq6 mfu8
20 Oct 20
Entry into a Material Definitive Agreement
4:15pm
8-K
rn1ro leeemo550r
16 Oct 20
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock
7:45am
8-K
s9nv2n673etp
13 Oct 20
Entry into a Material Definitive Agreement
4:15pm